Bioavailability and relative tissue distribution of [125I]‐recombinant human thrombin following intravenous or subcutaneous administration to non‐human primates

Summary.  Background: Recombinant human thrombin (rhThrombin) is being developed as a general adjunct to hemostasis. Endogenous thrombin is rapidly inactivated by complex formation with antithrombin III and other inhibitors. It follows that these inhibitors will also inactivate any rhThrombin that reaches the systemic circulation. Objectives: Study goals were to determine the pharmacokinetic characteristics of [125I]‐rhThrombin and [125I]‐rhThrombin complexed to endogenous inhibitors, and the tissue distribution of rhThrombin‐associated radioactivity in non‐human primates. Hematology, serum chemistry and coagulation status were also monitored. Methods: [125I]‐rhThrombin was administered intravenously (i.v.; 3.5 U kg−1) or subcutaneously (s.c.; 350 U kg−1) to male cynomolgus monkeys. Plasma was analyzed for rhThrombin‐associated radioactivity and non‐compartmental analysis was used to determine the corresponding pharmacokinetic parameters. A size exclusion–high pressure liquid chromatography (SE–HPLC) method was used to quantitate rhThrombin complexes, non‐complexed rhThrombin, and free [125I]. Whole‐body gamma scintigraphy was used to follow radioactivity localization up to 72 h postdose. Results: No adverse events were observed following [125I]‐rhThrombin administration. The pharmacokinetic profile of rhThrombin‐associated radioactivity following i.v. injection was multi‐exponential with an initial half‐life of approximately 10 min. Following both i.v. and s.c. dosing, the terminal half‐life was approximately 15 h. SE–HPLC analysis revealed that rhThrombin was rapidly complexed to antithrombin III and other inhibitors in the systemic circulation following i.v. administration. Thus, rhThrombin‐associated radioactivity in the blood was complexed and presumed inactive. [125I]‐rhThrombin inhibitor complexes accumulated and were eliminated in the liver following both routes of administration. Conclusions: These data suggest that rhThrombin rapidly binds to endogenous inhibitors following either i.v. or s.c. administration.

[1]  P. Reitsma,et al.  Blood coagulation factors as inflammatory mediators. , 2005, Blood cells, molecules & diseases.

[2]  T. Carlson Clearance of thrombin in vivo: significance of alternative pathways , 1986, Molecular and Cellular Biochemistry.

[3]  S. Strukova Thrombin as a Regulator of Inflammation and Reparative Processes in Tissues , 2004, Biochemistry (Moscow).

[4]  Strukova Sm Thrombin as a Regulator of Inflammation and Reparative Processes in Tissues , 2001 .

[5]  M. Virat,et al.  Absorption and elimination of a‐thrombin and tranexamic acid after fibrin sealant application on resected livers in rabbits , 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[6]  H. Takahashi,et al.  A case of delayed death after accidental intravenous injection of thrombin , 1998, International Journal of Legal Medicine.

[7]  F. Podlaski,et al.  IL-12: monoclonal antibodies specific for the 40-kDa subunit block receptor binding and biologic activity on activated human lymphoblasts. , 1991, Journal of immunology.

[8]  J. Wesley,et al.  A study of the lethal effects of intravenous injection of thrombin in rabbits. , 1990, Annals of Ophthalmology.

[9]  J Jesty,et al.  The kinetics of inhibition of alpha-thrombin in human plasma. , 1986, The Journal of biological chemistry.

[10]  P. Lollar,et al.  Clearance of thrombin from circulation in rabbits by high-affinity binding sites on endothelium. Possible role in the inactivation of thrombin by antithrombin III. , 1980, The Journal of clinical investigation.

[11]  R. Rosenberg,et al.  The isolation and characterization of a specific antibody population directed against the thrombin antithrombin complex. , 1980, Journal of Biological Chemistry.

[12]  H. Kingdon,et al.  Correlation of in vivo and in vitro inhibition of thrombin by plasma inhibitors. , 1979, Journal of Laboratory and Clinical Medicine.